ObjectiveTo explore the risk factors of hematostaxis after defibrinogen therapy in acute cerebral infarction patients. Methods80 patients with acute cerebral infarction, who underwent defibrinogen therapy in our hospital from September 2015 to December 2017, were enrolled as the objects. CT or MRI of head were repeatly performed, and its results were used as the basis for the diagnosis of hematostaxis. Patients were divided into hemorrhage group and non-hemorrhage group according to the presence of hematostaxis, performing univariate analysis and multivariate logistic regression analysis on the factors affecting hematostaxis. ResultsAmong the 80 patients with acute cerebral infarction treating with defibrinogen therapy, 18 patients of them emerged hematostaxis, with the incidence rate 22.5%. Univariate analysis revealed that NIHSS scores, large area cerebral infarction rate, cortical infarction rate, cardiogenic cerebral infarction rate and uric acid level in the hemorrhage group were significantly higher than the non-hemorrhage group, with statistically significant difference (P＜0.05). Multivariate logistic regression analysis revealed that NIHSS scores, large area cerebral infarction, and cardiogenic cerebral infarction were independent risk factors for hematostaxis after defibrinogen therapy on patients with acute cerebral infarction. ConclusionHigh NIHSS scores, large-area cerebral infarction, and cardiogenic infarction are independent risk factors for hematostaxis after defibrinogen therapy on patients with acute cerebral infarction. It is necessary to consider comprehensively whether defibrinogen therapy is employed to patients or not, so as to reduce the incidence of hematostaxis transformation.

无